SECUADO
Peakasenapine
NDATRANSDERMALSYSTEM
Approved
Oct 2019
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
11
Mechanism of Action
Pharmacologic Class:
Atypical Antipsychotic
Clinical Trials (5)
Asenapine for Bipolar Depression
Started Sep 2013
51 enrolled
Bipolar Depression
Observational Post-Authorisation Safety Study of Asenapine (Sycrest)
Started Oct 2012
1,000 enrolled
Manic Disorder
Antidepressant Plus Asenapine Versus Antidepressant Plus Placebo for Depression
Started Oct 2012
46 enrolled
Major Depressive Disorder Without Psychotic Features
A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Tolerability of Asenapine With Flexible Dosing From 5mg to 20mg in Adults With Developmental Stuttering
Started Sep 2012
32 enrolled
Stuttering
An Open Label Pilot Study of Adjunctive Asenapine for the Treatment of Posttraumatic Stress Disorder
Started Jun 2012
18 enrolled
Posttraumatic Stress Disorder
Loss of Exclusivity
LOE Date
Sep 22, 2033
91 months away
Patent Expiry
Sep 22, 2033